Key facts
- This page summarizes Jeffrey A. Rona's Form 4 filing for Ovid Therapeutics Inc. (OVID).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 24 Feb 2025, 19:55.
Jeffrey A. Rona - 20 Feb 2025 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)
- SEC form
- 4
- Accepted by SEC
- 24 Feb 2025, 19:55:07 UTC
- Prior SEC filing
- 19 Dec 2024
- Next SEC filing
- 28 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jason Minio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey A. Rona filed Form 4 for Ovid Therapeutics Inc. (OVID) on 24 Feb 2025.
Change
- Previous filing in this sequence was filed on 19 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OVID
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +43,750
- Change %
- +156%
- Price
- $0.000000
- Shares after
- 71,875
- Date
- 20 Feb 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OVID
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +262,500
- Change %
- Price
- $0.000000
- Shares after
- 262,500
- Date
- 20 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 262,500
- Exercise price
- $0.5700
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents a restricted stock unit ("RSU") award. The RSUs will vest in three equal annual installments commencing on February 22, 2026, subject to the Reporting Person's continuous service through each such vesting date.
Footnote F2
Each RSU represents a contingent right to receive one share of Common Stock.
Footnote F3
The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2025, subject to the Reporting Person's continued services through each such date.